



## Biobank and Registry for Pancreatic Patients



# Balázs Németh

First Department of Medicine, University of Szeged  
Hungarian Pancreatic Study Group

## Genetic Testing in Hungary

13th November 2016  
Budapest

## Genetic testing – children

1. **acute / recurrent acute / chronic** pancreatitis
2. testing is **independent from etiology**
3. **pancreatitis under 19** years of age  
at the time of diagnosis  
independent from actual age

Analyses of Pediatric Pancreatitis



**APPLE-P**

Analyses of Pediatric Pancreatitis



**APPLE-R**

## Genetic testing – Adults

### Adult patients with pancreatitis


1. **recurrent acute pancreatitis**  
at least 2 acute episodes
2. **chronic pancreatitis**
3. **pancreatitis** under 35 years of age  
at the time of diagnosis  
independent from actual age
4. Etiology is unknown (IDIOPATHIC)

## Genetic testing – Documents

1. **Informed consent** form of **genetic testing**
2. Informed consent form of **APPLE study / other register**
3. Completed electronic **APPLE / other registry form** on [www.pancreas.hu](http://www.pancreas.hu)
4. Patient's **referral for Genetic Counseling** by the therapist doctor (Pediatritian / GI).  
Referral have to be addressed to the Department of Medical Genetics, University of Szeged
5. 2 x 6 mL **EDTA anticoagulated blood collected** from the patient and sent to First Department of Medicine, University of **Szeged**

## Genetic testing – Applied methods

1. Isolation of **genomic DNA** from whole blood
2. Specific conventional **PCR** amplification of certain exons and their harbouring intronic regions
3. Sanger **sequencing** (conventional)
4. **Mutation analysis** of sequenced PCR products  
*manual detection of mutations*  
*sequence alignment program*
5. **Documented genetic counseling**  
*explanation of laboratory results and clinical significance of detected mutation(s)*  
*clinical genetician AND scientist together (2 professionals with the patient)*
6. **Informing therapist doctor about the results**



## Genetic testing – Sanger sequencing

### ADVANTAGES:

1. **GOLD STANDARD** method
2. Suitable for detection of **missense, nonsense, silent, splice-site mutations, and other intronic and promoter variants**
3. Detection of **microdeletions / microinsertions**
4. Detection of **novel (yet unknown) mutations**

### DISADVANTAGES:

1. **EXPENSIVE** (needs a lot of **time** and **money**)
2. **Unable to detect large deletions / insertions, copy number variations, haplotypes**

## Genetic testing – [www.pancreasgenetics.org](http://www.pancreasgenetics.org)

**PRSS1** 76 mutations (68 in 2015) – 26 pathogenic (26 in 2015)

**exon 2** – 10 pathogenic (p.A16V, p.N29I, p.N29T)

**exon 3** – 12 pathogenic (p.R122H, p.R122C)

**SPINK1** 91 mutations (79 in 2015) – 29 pathogenic (26 in 2015)

**exon 3** – 10 pathogenic (p.N34S) (9 in 2015)

**CTRC** 86 mutations (82 in 2015) – 33 pathogenic (33 in 2015)

**exon 2** – 4 pathogenic

**exon 3** – 7 pathogenic (p.G60G)

**exon 7** – 14 pathogenic (p.R254W)

**CPA1** 141 mutations

**exon 7, exon 8, exon 10**

**CFTR** **exon 4 (p.R117H), exon 11 (p.F508del)**

Hungarian Pancreatic Study Group – Eastern and Central European Pancreatic Study Groups

## Genetic testing

### Genetic test results

Registry code of blood sample:

**P5392**

Registry code of patient:

**APPLE-R 10101010**

### Summary of results

**Indication:**

**Purpose of genetic testing:**

**Results:**

**Comment:**

A clear and independent causative factor of hereditary pancreatitis is the p.R122H mutation in the *PRSS1* gene, that was NOT/- identified in the examined patient. Other mutations in the investigated genes are not independent risk factors, however may increase the risk of pancreatitis. Predisposing mutations and /or environmental factors are simultaneously susceptible for developing pancreatitis.

## Genetic testing – Negative test results – example

**Indication:** One episode of acute pancreatitis occurred in childhood (13 years of age).  
Idiopathic etiology / abdominal trauma.

**Purpose of genetic testing:** Genetic testing of genes are known to be associated with pancreatitis (*PRSS1*, *CTRC*, *SPINK1*, *CPA1* and *CFTR*).

**Results:** We did not identified a mutation that is known to be associated with pancreatitis in the genetic sample of the investigated patient.

**Comment:** Genetic testing could not confirm hereditary pancreatitis. Genetic risk factors were not identified.

## Genetic testing – Positive test results – example 1.

**Indication:** Recurrent acute pancreatitis, first episode was diagnosed under 19 years of age. Negative family history.

**Purpose of genetic testing:** Genetic testing of genes are known to be associated with pancreatitis (*PRSS1*, *CTRC*, *SPINK1*, *CPA1* and *CFTR*).

**Results:** We identified homozygous *CTRC* p.G60G mutation in the genetic sample of the investigated patient.

**Comment:** Genetic testing could not confirm hereditary pancreatitis, however *CTRC* p.G60G mutation in homozygous form elevates the risk of pancreatitis by 10-fold.

## Genetic testing – Positive test results – example 2.

**Indication:** Recurrent acute / Chronic pancreatitis developed in childhood.  
Positive family history.

**Purpose of genetic testing:** Genetic testing of genes are known to be associated with pancreatitis (*PRSS1*, *CTRC*, *SPINK1*, *CPA1* and *CFTR*).

**Results:** We identified heterozygous *PRSS1* p.R122H mutation in the genetic sample of the investigated patient.

**Comment:** Genetic testing confirmed hereditary pancreatitis.

## Genetic testing – Detailed description

**Genetic sample:** peripheral blood of the patient was sent to our laboratory by his/her physician with the purpose of research. Samples were identified only by registry code.

**Method of genetic testing:** .... Next slides

**Detailed results:** all of the variants we found in the investigated genes of the examined patient.

***CPA1*** c.697-367A>G heterozygous, c.697-260C>G heterozygous, c.697-63\_-62insCC heterozygous, c.787+234G>C heterozygous, c.1073-32A>G heterozygous,

***CFTR*** c.1408A>G p.M470V heterozygous.

**Citation**

**Date and signature**

## Genetic testing – what should we tell to the patients?

1. What kind of **mutation(s)** did we find?  
**causative: *PRSS1* (p.R122H)**  
**predisposing: *SPINK1, CTRC, CPA1, CFTR***  
harmless
2. What is the chance to get pancreatitis?  
understanding Odds ratio
3. **Almost all of the pathogenic mutations predispose to develop pancreatitis  
BUT usually they DO NOT cause the disease by themselves!**
4. **!!! DO NOT SMOKE and DO NOT DRINK ALCOHOL !!!**
5. Children should **EAT NORMALLY** / **NO STRICT RESTRICTION OF FAT INTAKE**, if they are otherwise healthy  
(but be careful with high fat diet in adulthood)

## Genetic testing – what should we tell to the patients?

It is **NOT recommended** to test patient's family members with **NO EPISODE** of acute pancreatitis.

If we **DO NOT FIND** any causative or predisposing mutation, **IT DOES NOT MEAN** that the patient **DOES NOT HAVE** genetic risk at all.

**Cancer risk** in case of hereditary pancreatitis (*PRSS1* p.R122H) by the age of 75 is  
**~50%\***

**!!!!Smoking and diabetes mellitus are the main associated risk factors!!!!**

\*Rebours V, Boutron-Ruault MC, Schnee M, Férec C, Maire F, Hammel P, Ruzsniowski P, Lévy P. (2008) **Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series.**  
Am J Gastroenterol.;103(1):111-9.



## Biobank and Registry for Pancreatic Patients



# Thank you for your attention!

The Hungarian Pancreatic Study Group is committed to improving the lives of patients suffering from pancreatic diseases.

[www.pancreas.hu](http://www.pancreas.hu)

## Sponsors of the Conference



**BERLIN-CHEMIE**  
**MENARINI**



RICHTER GEDEON



UNICAM  
Magyarország Kft.

OLYMPUS



MERCK